Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director

Hepion Pharmaceuticals, Inc. (CTRV) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 D Form D - Notice of Exempt Offering of Securities:
10/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Pre-Funded Warrant",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Sheppard, Mullin, Richter & Hampton LLP Legal Opinion",
"Form of Securities Purchase Agreement",
"Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules EDISON, N.J., September 29, 2023 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis , fibrotic diseases, hepatocellular carcinoma , and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement,..."
10/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/24/2023 8-K Quarterly results
07/21/2023 8-K Quarterly results
07/21/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT",
"Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split EDISON, NJ, / May 10, 2023 / Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis , hepatocellular carcinoma , and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023. Hepion common stock will begin trading on a split-adjusted basis when the market opens on May 11, 2023 under the existing trading symbol “HEPA.” As a result of the reverse stock split, the CUSIP number for the Company’ s common stock will now be 42689..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
12/15/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/21/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/15/2022 D Form D - Notice of Exempt Offering of Securities:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/08/2022 8-K Quarterly results
10/17/2022 8-K Investor presentation
Docs: "Hepion Pharmaceuticals, Inc. Corporate Presentation"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/05/2022 8-K Quarterly results
07/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/28/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/24/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2022 8-K Quarterly results
05/31/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/27/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy